Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
RNU4-92P is an annotated pseudogene in the human genome for the U4 small nuclear RNA[4][7]. Unlike the functional RNU4-2 gene, which encodes U4 snRNA required for spliceosome activity and is implicated in neurodevelopmental disorders, RNU4-92P is not transcribed into a functional RNA, nor does it partake in pre-mRNA splicing. There are no known biological functions, disease associations, or therapeutic applications for RNU4-92P. Most available information about U4 snRNA pseudogenes comes from comparative genomics, with evidence that such pseudogene copies exist in multiple species and are usually truncated or lack regulatory elements required for expression[7]. The recent surge in clinical and functional studies of U4 snRNA is centered on its active gene (RNU4-2), not the pseudogene RNU4-92P.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on RNA, U4 small nuclear 92, pseudogene (RNU4-92P).